Polymorphisms of the Flavin containing monooxygenase 3 (FMO3) gene do not predispose to essential hypertension in Caucasians. by Dolan, Ciara et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
Molecular and Cellular Therapeutics Articles Department of Molecular and Cellular Therapeutics
2-12-2005
Polymorphisms of the Flavin containing
monooxygenase 3 (FMO3) gene do not
predispose to essential hypertension in Caucasians.
Ciara Dolan
Royal College of Surgeons in Ireland
Denis C. Shields
University College Dublin
Alice Stanton
Royal College of Surgeons in Ireland
Eoin O'Brien
Beaumont Hospital, Dublin
Deborah M. Lambert
Children's University Hospital, Dublin
See next page for additional authors
This Article is brought to you for free and open access by the Department
of Molecular and Cellular Therapeutics at e-publications@RCSI. It has
been accepted for inclusion in Molecular and Cellular Therapeutics Articles
by an authorized administrator of e-publications@RCSI. For more
information, please contact epubs@rcsi.ie.
Citation
Dolan C, Shields DC, Stanton A, O'Brien E, Lambert DM, O'Brien JK, Treacy EP. Polymorphisms of the Flavin containing
monooxygenase 3 (FMO3) gene do not predispose to essential hypertension in Caucasians. BMC Medical Genetics. 2005 Dec 2;6:41.
Authors
Ciara Dolan, Denis C. Shields, Alice Stanton, Eoin O'Brien, Deborah M. Lambert, John K. O'Brien, and
Eileen P. Treacy
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/mctart/65
— Use Licence —
Attribution-Non-Commercial-ShareAlike 1.0
You are free:
• to copy, distribute, display, and perform the work.
• to make derivative works.
Under the following conditions:
• Attribution — You must give the original author credit.
• Non-Commercial — You may not use this work for commercial purposes.
• Share Alike — If you alter, transform, or build upon this work, you may distribute the resulting work only
under a licence identical to this one.
For any reuse or distribution, you must make clear to others the licence terms of this work. Any of these
conditions can be waived if you get permission from the author.
Your fair use and other rights are in no way affected by the above.
This work is licenced under the Creative Commons Attribution-Non-Commercial-ShareAlike License. To
view a copy of this licence, visit:
URL (human-readable summary):
• http://creativecommons.org/licenses/by-nc-sa/1.0/
URL (legal code):
• http://creativecommons.org/worldwide/uk/translated-license
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/mctart/65
BioMed Central
Page 1 of 7
(page number not for citation purposes)
BMC Medical Genetics
Open AccessResearch article
Polymorphisms of the Flavin containing monooxygenase 3 (FMO3) 
gene do not predispose to essential hypertension in Caucasians
Ciara Dolan1, Denis C Shields2, Alice Stanton1, Eoin O'Brien3, 
Deborah M Lambert4, John K O'Brien1 and Eileen P Treacy*5
Address: 1Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, 123 St Stephens Green, Dublin 2, Ireland, 2Conway 
Institute, University College Dublin, Dublin 4, Ireland, 3ADAPT Centre, Beaumont Hospital and Department of Clinical Pharmacology, Royal 
College of Surgeons in Ireland, Dublin 2, Ireland, 4Department of Genetics, Children's University Hospital, Temple St, Dublin 1, Ireland and 
5National Centre for Inherited Metabolic Disorders, Children's University Hospital, Temple St., Dublin 1, Ireland
Email: Ciara Dolan - cdolan@rcsi.ie; Denis C Shields - denis.shields@ucd.ie; Alice Stanton - astanton@rcsi.ie; Eoin O'Brien - eobrien@iol.ie; 
Deborah M Lambert - debby.lambert@olhsc.ie; John K O'Brien - jkobrien@rcsi.ie; Eileen P Treacy* - eileen.treacy@tsch.ie
* Corresponding author    
Abstract
Background: The recessive disorder trimethylaminuria is caused by defects in the FMO3 gene,
and may be associated with hypertension. We investigated whether common polymorphisms of the
FMO3 gene confer an increased risk for elevated blood pressure and/or essential hypertension.
Methods: FMO3 genotypes (E158K, V257M, E308G) were determined in 387 healthy subjects with
ambulatory systolic and diastolic blood pressure measurements, and in a cardiovascular disease
population of 1649 individuals, 691(41.9%) of whom had a history of hypertension requiring drug
treatment. Haplotypes were determined and their distribution noted.
Results: There was no statistically significant association found between any of the 4 common
haplotypes and daytime systolic blood pressure in the healthy population (p = 0.65). Neither was
a statistically significant association found between the 4 common haplotypes and hypertension
status among the cardiovascular disease patients (p = 0.80).
Conclusion: These results suggest that the variants in the FMO3 gene do not predispose to
essential hypertension in this population.
Background
Essential hypertension is the most common reason for
adult visits to office-based physicians and for the use of
medication [1-3]. It is estimated that 24% of the US adult
population (70% in persons over 70) and at least 50% of
the Irish adult population aged 50 or over are hyperten-
sive[4,5]. Ethnic differences exist in the prevalence of
hypertension between populations, for example between
Africans and Northern Europeans [6-8]. Mendelian forms
of hypertension resulting from single gene defects are rare
[9-11]. The major contribution to the etiology of this dis-
order is proposed to result from the combined effects of
genes that modify the response of blood pressure to envi-
ronmental stresses such as diet and 'environmental sus-
ceptibility genes' [12-14]. Essential hypertension does not
follow a clear pattern of inheritance but exhibits familial
aggregation of cases. This multifactorial trait increases the
affected individuals' risk of myocardial infarction, stroke
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and end-stage renal disease, and is one of the leading
causes of morbidity and mortality in adults[8,15]. Popu-
lation-wide application of preventative measures and can-
didate gene analysis to predict modifiable risks in
addition to treatment are thus very worthwhile [16-19].
Trimethylaminuria (TMAuria) is an inborn error of
metabolism (MIM # 275700) resulting from diminished
oxidation of the tertiary amine trimethylamine to trimeth-
ylamine N-oxide resulting in a severe body odour in
affected individuals. The microsomal NADPH-dependent
flavin-containing monooxygenases (FMOs) (E.C.
1.14.12.8) are a family of chemical and drug metabolising
enzymes that catalyze the phase 1 oxygenation of a wide
variety of nucleophilic heteroatom containing com-
pounds including catecholamines[20,21]. FMO3, a phase
1 drug metabolising gene, is the main liver dependent
human isoform[22]. We and others have shown that
recessivity for mutations of FMO3 cause TMAuria [20-24].
We have previously noted that a number of patients with
TMAuria have idiopathic hypertension [21,22]. In addi-
tion, Cashman et al [25] have reported a proposed link in
African-American males between hypertension and
increased excretion of trimethylamine. We have identified
increased excretion of catecholamines in a proband with
TMAuria who is homozygous for a deletion of the FMO3
gene [20]suggesting a possible association between
abnormal catecholamine metabolism and variants of the
FMO3 gene. Endogenous substrates for FMO3 include
tyramine and phenylethylamine [26,27] and tyramine has
a known pressor effect. As high levels of circulating cate-
cholamines contribute to hypertension, it is proposed that
polymorphisms of FMO3 gene could contribute to
impaired catecholamine metabolism and hypertension.
We have previously described the population frequencies
of a number of common polymorphisms of the FMO3
gene (E158K, V257M, E308G) in a North American pop-
ulation[25,28]. Expression studies indicate that the poly-
morphisms E158K and V257M exhibit decreased
tyramine oxidation in vitro[25]. We and others have noted
that the E308G polymorphism shows a substantial
decrease in FMO3 activity in the presence of the E158K
polymorphism causing mild TMAuria[22,29]. While these
common polymorphisms exhibit some difference in
expression of the functional FMO3 enzyme, this effect is
minimal in comparison to that of the null mutations.
We hypothesised that common FMO3 polymorphisms
might predispose to essential hypertension. While null
alleles in the FMO3 gene may be too rare to cause any
appreciable effect on the population burden of hyperten-
sion, prevalent polymorphisms with documented in vitro
evidence of variation in catecholamine metabolism may
however potentially associate with and predispose to this
condition.
Herein we report our investigations into a possible associ-
ation of haplotypes of three polymorphic variants of the
FMO3 gene with the phenotype of blood pressure in an
occupational Irish adult population and with presence of
essential hypertension in an Irish cardiovascular disease
(CVD) population.
Methods
Study populations
There were 2 population groups in this study. The first
population was recruited from the Allied Irish Bank Phase
II (AIB Phase II) study that commenced in 1989 and con-
sists of 387 bank employees (Table 1). Blood pressure was
measured every 30 minutes for 24 hours using a validated
monitor – the SpaceLabs 90207. The mean daytime and
night time systolic (SBP) and diastolic (DBP) values were
used for analysis in each case. Hypertension was defined
as having daytime blood pressure of 135/85 mm Hg or
greater. This group was collected between 1998 and 2002
and was between the ages of 30–70 years. It was noted if
individuals consumed more than 2 alcohol-containing
drinks per day.
The second were a group of 1649 patients with coronary
disease (CHD), 1313 of whom were ascertained on the
basis of having acute coronary syndromes (ACS) (myocar-
dial infarction (MI) or unstable angina) and 336 as having
stable angina (Table 2). MI was defined as chest pain of at
least 20 minutes duration, along with previous or current
Table 1: Characteristics of AIB Phase II study group
Male Mean/SD* 
(n = 224)
Female Mean/SD* 
(n = 163)
Age (years) 52.5 +- 9.2 47.4 +- 10.0
Weight (KG) 85.7 +- 16.1 66.3 +- 13.7
Height (cm) 177.5 +- 12.6 163.1 +- 11.3
Hypertensive 3.1% 1.2%
Daytime systolic BP (mmHg) 128.2 +- 10.3 118.3 +- 9.9
Daytime diastolic BP (mmHg) 80.8 +- 7.7 75.6 +- 7.3
Nighttime systolic BP (mmHg) 108.7 +- 9.8 101.5 +- 8.6
Nighttime diastolic BP (mmHg) 62.5 +- 7.5 58.1 +- 6.3
Total cholesterol (mmol/L) 5.7 +- 1.2 5.3 +- 1.2
Triglycerides (mmol/L) 1.5 +- 0.9 1.0 +- 0.6
Diabetes mellitus (%) 0.8% 0.6%
Smokers (Current/Ex) (%) 32.4% 27.9%
Medication:
Antihypertensive (%) 3.6% 3.7%
Hormone replacement therapy 0% 21%
Anti-arrhythmic 0.5% 0%
*Standard deviation
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electrocardiogram or serum enzyme changes diagnostic of
MI. Unstable angina was defined as chest pain typical of
angina occurring at rest or lasting at least 20 minutes and
requiring hospitalization in a patient with known coro-
nary artery disease based on a positive stress test or a cor-
onary angiogram. Inclusion criteria for stable angina were
chest pain occurring with exercise typical of angina in a
patient with known coronary artery disease based on a
coronary angiogram or a positive treadmill test. These
patients were collected between the years 1999–2002 and
were between the ages of 32 and 85 years. They were clas-
sified as having a history of hypertension requiring drug
treatment or having no history of hypertension.
Informed consent and ethics approval from the Beaumont
Hospital Ethics (Medical Research) Committee was
obtained for all samples collected.
FMO3 polymorphism genotyping
Three single nucleotide polymorphisms in the FMO3 gene
were genotyped in the above populations. These were
E158K (G472A), V257M (G769A) and E308G (A923G).
The E158K polymorphism was genotyped using the
primer GAAGGTGACCAAGTTCATGCTTGGCCTTACCT-
GGAAAGGACTT for the G allele and GAAGGTCGGAGT-
CAACGGATTTTTGGCCTTACCTGGAAAGGACT for the A
allele. The V257M polymorphism was genotyped using
the primer GAAGGTGACCAAGTTCATGCT-
CAGCCATCTCTGACTGGTTGTACA for the G allele and
GAAGGTCGGAGTCAACGGATTAGCCATCTCTGACT-
GGTTGTACG for the A allele. The E308G polymorphism
was genotyped using the primer GAAGGTGACCAAGT-
TCATGCTGCCTAACGTGAAGGAATTCACAGA for the A
allele and GAAGGTCGGAGTCAACGGATTGCCTAACGT-
GAAGGAATTCACA for the G allele.
Genotyping was carried out using the Amplifluor™
method by K Biosciences http://www.kbioscience.co.uk.
Genomic DNA was isolated from blood. Genotyping was
performed in 384-well microplates using a fluorescence
resonance energy transfer (FRET)-based genotyping
method. Amplification was initiated using allele-specific
primers and a common downstream primer. The allele-
specific primers were tailed with unique sequences that
create corresponding complementary sequences in the
two amplicons. In the second round of amplification,
quenched Universal Amplifluor™ primers (in a hairpin
formation) were used. These primers contain 3' tails that
specifically bind to the unique tailed sequences in the
amplicons and continue amplification. In the final round
of amplification, the action of the DNA polymerase
opened up the hairpin structure and the quencher and
reporter moieties are spatially separated. The excited
reporter moiety emitted either red or green fluorescence,
the colour of which depends on which nucleotide is at the
polymorphism site. The fluorescence was quantified by a
microplate reader and then analysed via an Excel macro to
provide genotypes for each SNP. Confirmation of the val-
idation of the mutation detection method was based on
the use of known positive DNA controls (which had been
sequenced) for the three polymorphisms provided by
McGill University (Montreal).
Haplotype analysis
Haplotypes for the 3 SNPs were inferred using a maxi-
mum likelihood approach and their association with the
rank of the various mean blood pressure measurements in
the AIB Phase II study group and their association with
hypertension in the CVD group was determined using
"haplo.score", a function written for the statistical pack-
age SPLUS 6.0[30]. This method used score tests for asso-
ciation between a quantitative trait and the haplotypes.
The result of the association was given as a haplotype
score. The haplotypes score was calculated using a general
linear model, which permitted adjustment for age, sex and
alcohol consumption.
Statistical analysis
The 2 primary analyses were (1) the association between
haplotypes of the 3 SNPs and mean daytime systolic
blood pressure in the AIB Phase II study population and
(2) the association between haplotypes and the hyperten-
sion status in the CVD patients.
The secondary analyses included (1) the association
between genotypes and daytime systolic blood pressure in
the AIB Phase II study, (2) the association between geno-
types and hypertensive status in the CVD group, (3) the
comparison of genotypic frequencies between the AIB
Phase II study group, the hypertensives of the CVD group
and the non-hypertensives of the CVD group, (4) the
Table 2: Characteristics of Cardiovascular disease group
Hypertensive 
Mean/SD*
(n = 691)
Non-hypertensive 
Mean/SD*
(n = 958)
Age (years) 62.5 +/- 7.9 60.4 +/- 8.7
Weight (KG) 79.1 +/- 19.7 77.5 +/- 18.4
Height (cm) 160.3 +/- 34.9 163.1 +/- 34.3
Gender (males) 66.8% 83.6%
Hypercholesterolemia (%) 68.3% 51.7%
Diabetes mellitus (%) 12.9% 6.8%
Smokers (Current/Ex) (%) 69.9% 76.9%
Aspirin (%) 99.0% 99.2%
Statins (%) 96.3% 98.5%
B-Blockers (%) 95.9% 97.9%
Nitrates (%) 91.7% 95.4%
Calcium channel blockers (%) 92.2% 92.7%
ACE inhibitors (%) 92.2% 91.9%
*Standard deviation
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effect of haplotypes on mean daytime diastolic blood
pressure, on mean night time systolic blood pressure and
on mean night time diastolic blood pressure in the AIB
Phase II study group, (5) the association between poly-
morphisms in the FMO3 gene and cardiovascular disease.
Haplo.score was used to look for any associations
between haplotypes and daytime systolic blood pressure/
hypertensive status. We only tested for relatively common
haplotypes, and defined as those at an inferred frequency
of greater than 5% in the populations. For all of the above
analyses, statistical significance was determined when p <
0.05.
ANOVA was used to look for an association between the
genotypes and mean daytime systolic blood pressure in
the AIB Phase II study group. Both haplo.score and
ANOVA were adjusted for age, sex and the number of
alcohol units consumed per week.
Chi-squared analysis was used to look for the difference in
genotype frequencies between the hypertensive and non-
hypertensive patients in the CVD group. Linear regression
was then used to adjust for age and sex. Chi-squared anal-
ysis was also used to compare genotypic frequencies
between the AIB Phase II study group, the hypertensives
from the CVD group and the non-hypertensives of the
CVD group. Logistic regression analysis was used to pre-
dict if any of the SNPs influence the risk of cardiovascular
disease, including diabetes, BMI, hypercholesterolemia,
smoking status, age and gender in the model. All of the
above analyses were repeated stratifying according to gen-
der.
Results
The AIB Phase II population consisted of 387 subjects,
224 (57.8%) of which were male. In comparison to the
females, the males had on average higher blood pressure
measurements, triglycerides and total cholesterol. Slightly
more males in this group were smokers (Table 1).
The CVD group consisted of 1649 subjects, 691 (41.9%)
of which were classified as having a history of hyperten-
sion requiring drug treatment. A greater percentage of
those classified as hypertensive also had hypercholestero-
lemia and diabetes mellitus in comparison to those who
were classified as non-hypertensive. As might be expected
from a CVD group, most of the subjects were taking med-
ication, with almost the same frequency of hypertensives
and non-hypertensives taking each group of medications
(Table 2). Blood pressure measurements are only pre-
sented to characterise, rather than compare, the groups,
since medication is lowering blood pressure in most of
the CHD group, but not in most of the AIB Phase II study
group.
The most notable difference between the AIB Phase II
study group and the CVD group is that there were a much
greater proportion of current or ex smokers in the CVD
group than in the AIB Phase II study group (73% vs.
30.1%).
The 3 SNPs were found to be in Hardy-Weinberg Equilib-
rium. 4 common haplotypes were inferred in the two pop-
ulations (Table 3), with similar frequencies in the AIB
Phase II study group, the hypertensives and in the non-
hypertensives of the CVD group. However the haplotype
KVG, which is the 2nd most frequent haplotype in the AIB
Phase II study group, was the 3rd most frequent haplotype
in the CVD group. However the difference in frequency
was only 4%, which is most likely due to chance.
No statistically significant associations were found
between any of the four common haplotypes and mean
daytime systolic blood pressure in the AIB Phase II study
(overall p = 0.65, 3 d.f) (See table 3). Nor was this statis-
tically significant when adjusted for age, sex and daily
alcohol intake (overall p = 0.729, 3 d.f) (See table 3). Nei-
ther did we find any statistically significant associations
between any of the haplotypes and hypertension status in
all subjects with and without adjustment of sex and age
(see table 3). When stratified by gender, there were still no
statistically significant associations between any of the
specific haplotypes and daytime SBP in the AIB Phase II
study (males overall p = 0.91, 3 df and females overall p =
0.61, 3 df) or with hypertension status in the CVD
patients (males overall p = 0.59, 3 df and females overall
p = 0.82, 3 df). Table 4 displays the genotypic frequencies
of the 3 SNPs in the AIB Phase II population, in the hyper-
tensives of the CVD group and in the non-hypertensives
of the CVD group. When genotypic frequencies were com-
pared among 3 groups, there were no statistically signifi-
cant differences (E158K p = 0.30, V257M p = 0.47, E308G
p = 0.15). There were no statistically significant associa-
tions between any of the individual genotypes with day-
time SBP in the AIB Phase II study group, even when
adjusted for age, sex and daily alcohol consumption
(E158K p = 0.91, V257M p = 0.85, E308G p = 0.68).
The mean daytime SBP and mean daily alcohol consump-
tion are broken down by genotype in table 5 and it is clear
that there is not much difference between the genotype
groups. Stratifying the analysis by gender, there was still
no association between genotypic frequencies in the AIB
Phase II study group (females E158K p = 0.92, V257M p =
0.86, E308G p = 0.13, males E158K p = 0.37, V257M p =
0.87, E308G p = 0.38).
There was no genotypic difference between hypertensive
and non-hypertensive CVD subjects, even after adjust-
ment for age and sex (E158K p = 0.84, V257M p = 0.44,
BMC Medical Genetics 2005, 6:41 http://www.biomedcentral.com/1471-2350/6/41
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E308G p = 0.91). When this analysis was stratified by gen-
der, still no statistically significant differences are noted
(females E158K p = 0.79, V257M p = 0.54, E308G p =
0.29, males E158K p = 0.71, V257M p = 0.22, E308G p =
0.66).
Testing for any associations between haplotype and day-
time diastolic blood pressure, night time systolic blood
pressure and night time diastolic blood pressure in the
AIB Phase II study yielded no statistically significant asso-
ciations (Table 6). Likewise it was shown by logistic
regression that none of the SNPs were significant predic-
tors for cardiovascular disease when the CVD and the AIB
Phase II study groups were compared (E158K z = 0.60 p =
0.55, V257M z = -0.31 p = 0.76, E308G z = 0.49 p = 0.63),
though diabetes was found to be a significant predictor.
Discussion
The observation that a number of patients with TMAuria
are hypertensive was the basis to the hypothesis that there
may be an association between variants in the FMO3 gene
and hypertension. The FMO3 enzyme has a broad sub-
strate specificity, which includes catecholamines as a
minor pathway[21,26]. Catecholamines are produced in
response to stress and modulate heart rate and blood pres-
sure. Variants of the FMO3 gene resulting in decreased
enzymatic activity could result in decreased catabolism of
catecholamines, which impact on blood pressure home-
ostasis. As catecholamines are at peak levels during the
day, we elected to study the association between daytime
SBP and variants in the FMO3 gene as a primary endpoint.
In our analysis, we adjusted for alcohol use as tyramine is
a substrate for FMO3 oxidation[26]. The FMO3 enzyme is
also modulated by the sex hormones[28]. Females with
moderate to severe TMAuria note exacerbations perimen-
strually and it is proposed that decreases in FMO3 enzy-
Table 3: Associations between haplotypes in the AIB Phase II group with daytime systolic blood pressure and in the CVD group with 
hypertension status.
AIB Phase II group CVD group
Haplotypes Freq Haplotype 
scoreb
p-value Haplotype 
scoreb*
p-value* Hypertensive 
freq
Non-hypertensive 
freq
Haplotype 
scoreb
p-value Haplotype 
scoreb†
p-value†
EVEa 50.5% 0.497 0.62 0.392 0.70 53.5% 54.4% -0.578 0.56 -0.715 0.47
KVGa 22.0% 0.638 0.52 0.629 0.51 18.0% 17.8% 0.206 0.84 0.433 0.66
KVEa 21.2% -0.669 0.50 -0.687 0.49 21.5% 21.7% -0.004 0.99 -0.073 0.94
EMEa 6.3% -0.954 0.34 -0.725 0.45 7.0% 6.1% 0.921 0.36 0.948 0.34
Overall p-
value
0.65 0.73 0.80 0.79
a haplotypes defined for positions 158, 257 and 308 respectively
b from the haplo.score method[30]
* Adjusted for age, sex and alcohol intake
† Adjusted for age and sex
Table 4: Tabulation of genotype percentages and frequencies in groups
Genotype (amino acid) AIB Phase II study (387) Hypertensive (775) Non-hypertensive (984)
E158K KK 19.4% (75) 14.6% (101) 16.0% (154)
EK 45.7% (177) 47.7% (330) 45.6% (439)
EE 33.8% (131) 35.1% (243) 37.1% (357)
Missing 1.1% (4) 2.6% (18) 1.3% (12)
V257M MM 1.0% (4) 0.4% (3) 0.3% (3)
VM 11.1% (43) 12.3% (85) 11.3% (109)
VV 86.3% (334) 86.4% (598) 87.6% (843)
Missing 1.5% (6) 0.9% (6) 0.7% (7)
E308G GG 5.7% (22) 3.3% (23) 3.3% (32)
GE 31.0% (120) 28.2% (195) 28.5% (274)
EE 61.2% (237) 66.9% (463) 66.8% (643)
Missing 2.1% (8) 1.6% (11) 1.4% (13)
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matic activity resulting from polymorphisms could also
be influenced by hormonal events[31]. For this reason the
analysis was stratified by treating males and females as
separate groups.
In this study, by constructing haplotypes based on the 3
SNPs, we discovered that none of the haplotypes were sta-
tistically significantly associated with either daytime
systolic blood pressure in the AIB Phase II study group or
with hypertensive status in the CVD group. There was also
a lack of association between any of the genotypes of the
SNPs with daytime SBP or with hypertension status. Nei-
ther did the stratified analyses show any statitically signif-
icant associations.
While the definition of hypertension in the CVD popula-
tion provides a rather arbitrary estimation of hyperten-
sion, the 24-hour blood pressure measurements in the
AIB Phase II study were carefully controlled. Even so, the
results from both groups showed that the variants had no
association with blood pressure or hypertension status.
Why are FMO3 variants maintained in population, and in
particular the E158K variant? It is proposed that genes
such as FMO3, a drug and toxin detoxicating gene, may
have survived as balanced polymorphisms in an ancient
human or primate population to neutralise the effect of
harmful exposures[32,33]. Evolutionary changes in
FMO3 may have evolved in different geographic locations
to buffer changes in the highly polymorphic drug metab-
olising genes, which show substantial geographic and eth-
nic variation. It is possible that 'low penetrance'
polymorphisms of FMO3 alone may not independently
affect blood pressure homeostasis but severe loss of func-
tion causing mutations may unmask pressor effects of var-
iation in other drug metabolising enzymes previously
buffered by FMO3[34]. This hypothesis is supported by
the observation that only some, but not all, TMAuria
patients exhibit hypertensive symptoms. Therefore other
common FMO genes may be potential hypertension can-
didates. There could be identified by typing other FMO
genes in TMAuria patients with hypertensive symptoms or
by directly assessing the candidate genes in a large study
of hypertension.
Conclusion
In conclusion, these data indicate that these three poly-
morphisms of the FMO3 gene inherited singly or in spe-
Table 6: Summary of haplotype scores representing associations between blood pressure and haplotypes in the AIB phase II 
population showing overall statistical significance values
Haplotypes (amino acid) EVEa KVGa KVEa EMEa Overall p-val
Daytime DBP Haplotype scoreb -0.136 -0.266 0.890 -0.726 0.76
Haplotype scoreb (adjusted*) -0.361 -0.192 0.985 -0.565 0.77
Nighttime SBP Haplotype scoreb -0.657 1.676 -0.576 -0.586 0.40
Haplotype scoreb (adjusted*) -0.803 1.676 -0.573 -0.294 0.42
Nighttime DBP Haplotype scoreb -1.313 1.313 0.665 -0.699 0.41
Haplotype scoreb (adjusted*) -1.453 1.177 0.706 -0.260 0.47
* Adjusted for age, sex and alcohol intake
a haplotypes defined from positions 128, 257 and 308 respectively
b from the haplo.score method
Table 5: Mean daytime systolic blood pressure and mean alcohol consumption broken down by genotype in the AIB Phase II study 
group.
Genotype (amino acid) Number subjects Mean daytime sbp/SD* Alcohol consumption +/- SD*
E158K KK 75 126.71 +- 13.1 12.87 +- 13.8
EK 177 125.87 +- 12.6 12.83 +- 12.4
EE 131 126.61 +- 13.2 14.81 +- 14.1
V257M MM 4 126.67 +- 9.3 14.00 +- 12.3
VM 43 121.25 +- 14.7 15.50 +- 16.7
VV 334 126.02 +- 12.7 13.24 +- 12.9
E308G GG 22 129.32 15.65
GE 120 125.82 11.87
EE 237 126.18 14.26
* Standard deviation
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cific haplotype combinations do not represent an
independent susceptibility risk for hypertension as an
absolute trait or continuous variable in a representative
Irish population.
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